ClinicalTrials.gg
CompletedNCT01265446Updated Apr 24, 2013Results posted

Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.

A Phase 3 interventional study of Lidocaine 8mg + CPC 2mg and Lidocaine 1mg + CPC 2mg in Sore Throat Due to a Common Cold, sponsored by Novartis. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.

Primary conditionRespiratory Tract InfectionsRegistry: PharyngitisReclassifiedWhy we changed it
Registry
Pharyngitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Respiratory Tract Infections
Why
  1. The registry often attaches Pharyngitis to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's title name Respiratory Tract Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies in Respiratory Tract Infections with a site in Germany — 7 open to participants now, 8 under way, 4 of them phase 3. Respiratory Tract Infections · Germany.

Enrollment
15th of 29
250 · median 250
Started
2010
with 1 other
Phase 3
15 of 38
4 open now
Registered
5th of 38
by date

Among the 38 studies in Respiratory Tract Infections with a site in Germany, this one is the 15th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2010, is one of 15 in phase 3, and was the 5th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

7 of the 38 studies in Respiratory Tract Infections with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Respiratory Tract Infections with a site in Germany, or all of them as a file.
02

Study summary

This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.

03

Conditions studied

  • Sore Throat Due to a Common Cold

Browse trials for

Keywords

  • Sore throat, upper respiratory tract infection, lozenge with lidocaine and cetylpyridinium chloride.
04

In context

Respiratory Tract Infections Reclassified

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

This study's enrollment of 250 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.

Browse Respiratory Tract Infections studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Compared within Respiratory Tract Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pharyngitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with sore throat due to an upper respiratory tract infection, with recent onset (within 48 hours)
  • Sore throat of at least moderate pain intensity

Exclusion criteria

Exclusion Criteria:

    • History of to any of the study drugs and listed or to drugs of similar chemical classes
  • Evidence of mouth breathing or severe coughing
  • Evidence of overt oropharyngeal bacterial or fungal infection or evidence of lower respirator tract infection
  • Severe renal, liver or cardiac impairment
  • Severe lung disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Lidocaine 8mg +CPC 2mg

    one single dose

    Drug: Lidocaine 8mg + CPC 2mg

  • Active comparator
    Lidocaine 1mg + CPC 2mg

    one single dose

    Drug: Lidocaine 1mg + CPC 2mg

Interventions

  • DrugLidocaine 8mg + CPC 2mg

    Drug page: Lidocaine

    one single dose

  • DrugLidocaine 1mg + CPC 2mg

    Drug page: Lidocaine

    one single dose

07

What researchers measure

Primary outcomes

  1. Change From Baseline Sore Throat Pain Intensity

    100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm)

    Time frame: Baseline and 2 hours post-dose

Secondary outcomes

  1. Change From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose

    100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm). It measures the highest pain level felt by the patient.

    Time frame: Baseline and 240 mn post-dose

08

Results

Posted Jul 26, 2012

Participant flow

14 Dec 2010 to 5 Apr 2011

Participant flow — Overall Study
MilestoneLidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mg
Started125125
Completed124125
Not completed10

Outcome measures

PrimaryChange From Baseline Sore Throat Pain Intensity

100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm)

Time frame:
Baseline and 2 hours post-dose
Reported as:
Mean · mm
Change From Baseline Sore Throat Pain Intensity
mmLidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mg
Change From Baseline Sore Throat Pain Intensity-27.4 (-31.0 to -23.8)-26.9 (-30.5 to -23.3)
SecondaryChange From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose

100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm). It measures the highest pain level felt by the patient.

Time frame:
Baseline and 240 mn post-dose
Reported as:
Mean · mm
Change From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose
mmLidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mg
Change From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose-25.5 (-29.8 to -21.2)-29.1 (-33.1 to -25.1)

Adverse events

Collected over 14 Dec 2010 to 5 Apr 2011. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lidocaine 8mg +CPC 2mg—1/125 (0.8%)10/125 (8%)
Lidocaine 1mg + CPC 2mg—0/125 (0%)9/125 (7.2%)
Most frequent serious events
Most frequent serious events
EventLidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mg
Tendon ruptureInjury, poisoning and procedural complications1/1250/125
Most frequent other events
Most frequent other events
EventLidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mg
HeadacheNervous system disorders7/1256/125
Throat IrritationRespiratory, thoracic and mediastinal disorders1/1251/125
AsthmaRespiratory, thoracic and mediastinal disorders0/1251/125
dizzinessNervous system disorders0/1251/125
hyperaesthesiaNervous system disorders1/1250/125
RashSkin and subcutaneous tissue disorders1/1250/125
StridorRespiratory, thoracic and mediastinal disorders1/1250/125
vertigoNervous system disorders1/1250/125

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mgTotal
<=18 years000
Between 18 and 65 years125125250
>=65 years000
Age Continuous
Age Continuous(years)Lidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mgTotal
Mean32.1 ± 12.631.6 ± 11.631.9 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Lidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mgTotal
Female6767134
Male5858116
Region of Enrollment
Region of Enrollment(participants)Lidocaine 8mg +CPC 2mgLidocaine 1mg + CPC 2mgTotal
Germany125125250
09

Study locations

1 site
  • Socratec
    Erfurt, Germany
10

References and documents

Publications

  • Donath F, Mallefet P, Garreffa S, Furcha R. Efficacy of 8 mg lidocaine and 2 mg cetylpyridinium chloride (CPC) fixed-combination lozenges on sore throat pain intensity compared with 1 mg lidocaine and 2 mg CPC fixed-combination lozenges in subjects with sore throat due to upper respiratory tract infection: a randomized double-blind parallel-group single-dose study. Trials. 2018 Dec 12;19(1):679. doi: 10.1186/s13063-018-3077-6. PubMed 30541606 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2010
First posted
Dec 23, 2010
Start
Dec 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Jul 26, 2012
Last update
Apr 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01265446
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Dec 23, 2010
Start date
Dec 2010
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Jul 26, 2012
Last update
Apr 24, 2013

Study contacts

Investigator
principal investigator · SocraTec R&D GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion